Cargando…
Triple combination therapy and zeaxanthin for the treatment of neovascular age-related macular degeneration: an interventional comparative study and cost-effectiveness analysis
BACKGROUND: Reports of triple combination therapy for neovascular age-related macular degeneration (AMD) suggest a benefit, as do reports for zeaxanthin. An interventional comparative study was thus undertaken to evaluate the efficacy of triple combination therapy with and without zeaxanthin, as wel...
Autores principales: | Olk, R. Joseph, Peralta, Enrique, Gierhart, Dennis L., Brown, Gary C., Brown, Melissa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088486/ https://www.ncbi.nlm.nih.gov/pubmed/27847615 http://dx.doi.org/10.1186/s40942-015-0019-2 |
Ejemplares similares
-
Prevention Surpasses Treatment: 5-year Follow-Up, Cost-Utility, and Cost–Benefit of Zeaxanthin Therapy for Neovascular Age-Related Macular Degeneration
por: Brown, Gary C., et al.
Publicado: (2023) -
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
por: Brown, Gary C., et al.
Publicado: (2017) -
A Value-Based Medicine cost-utility analysis of genetic testing for neovascular macular degeneration
por: Brown, Gary C., et al.
Publicado: (2015) -
Lutein and Zeaxanthin and Their Roles in Age-Related Macular Degeneration—Neurodegenerative Disease
por: Mrowicka, Małgorzata, et al.
Publicado: (2022) -
Cost-effectiveness of ranibizumab for neovascular age-related macular degeneration
por: Hurley, Susan F, et al.
Publicado: (2008)